tbuckley/cabot-search huggingface dataset:
Prediction of recurrent venous thrombosis in all patients with a first venous thrombotic event: The Leiden Thrombosis Recurrence Risk Prediction model (L-TRRiP)
Authors: Jasmijn F. Timp, Sigrid K. Braekkan, Willem M. Lijfering, Astrid van Hylckama Vlieg, John-Bjarne Hansen, Frits R. Rosendaal, Saskia le Cessie, Suzanne C. Cannegieter
Journal: PLoS Medicine (2019)

Background Recurrent venous thromboembolism (VTE) is common. Current guidelines suggest that patients with unprovoked VTE should continue anticoagulants unless they have a high bleeding risk, whereas all others can stop. Prediction models may refine this dichotomous distinction, but existing models apply only to patients with unprovoked first thrombosis. We aimed to develop a prediction model for all patients with first VTE, either provoked or unprovoked. Methods and findings Data were used from two population-based cohorts of patients with first VTE from the Netherlands (Multiple Environment and Genetic Assessment of Risk Factors for Venous Thrombosis [MEGA] follow-up study, performed from 1994 to 2009; model derivation; n = 3,750) and from Norway (Tromsø study, performed from 1999 to 2016; model validation; n = 663). Four versions of a VTE prediction model were developed: model A (clinical, laboratory, and genetic variables), model B (clinical variables and fewer laboratory markers), model C (clinical and genetic factors), and model D (clinical variables only). The outcome measure was recurrent VTE. To determine the discriminatory power, Harrell's C-statistic was calculated. A prognostic score was assessed for each patient. Kaplan-Meier plots for the observed recurrence risks were created in quintiles of the prognostic scores. For each patient, the 2-year predicted recurrence risk was calculated. Models C and D were validated in the Tromsø study. During 19,201 person-years of follow-up (median duration 5.7 years) in the MEGA study, 507 recurrences occurred. Model A had the highest predictive capability, with a C-statistic of 0.73 (95% CI 0.71–0.76). The discriminative performance was somewhat lower in the other models, with C-statistics of 0.72 for model B, 0.70 for model C, and 0.69 for model D. Internal validation showed a minimal degree of optimism bias. Models C and D were externally validated, with C-statistics of 0.64 (95% CI 0.62–0.66) and 0.65 (95% CI 0.63–0.66), respectively. According to model C, in 2,592 patients with provoked first events, 367 (15%) patients had a predicted 2-year risk of >10%, whereas in 1,082 patients whose first event was unprovoked, 484 (45%) had a predicted 2-year risk of <10%. A limitation of both cohorts is that laboratory measurements were missing in a substantial proportion of patients, which therefore were imputed. Conclusions The prediction model we propose applies to patients with provoked or unprovoked first VTE—except for patients with (a history of) cancer—allows refined risk stratification, and is easily usable. For optimal individualized treatment, a management study in which bleeding risks are also taken into account is necessary.
The Biologic and Analytic Variability of Serum Protein Electrophoresis M-Spike, Nephelometric Ig Quantitation, Serum FLC Quantitation, and Urine M-Spike in Monoclonal Gammopathies.
Authors: Melissa Snyder, Angela Dispenzieri, S.Vincent Rajkumar, Robert Kyle, Joanne Benson, Jerry A. Katzmann
Journal: Blood (2009)
Identification and Quantification of Cardiovascular Structures From CCTA
Authors: Lohendran Baskaran, Gabriel Maliakal, Subhi J. Al’Aref, Gurpreet Singh, Zhuoran Xu, Kelly Michalak, Kristina Dolan, Umberto Gianni, Alexander van Rosendael, Inge van den Hoogen, Donghee Han, Wijnand Stuijfzand, Mohit Pandey, Benjamin C. Lee, Fay Lin, Gianluca Pontone, Paul Knaapen, Hugo Marques, Jeroen Bax, Daniel Berman, Hyuk-Jae Chang, Leslee J. Shaw, James K. Min
Journal: JACC. Cardiovascular imaging (2019)
Excellent Outcome for ETV6/RUNX1-Positive Childhood Acute Lymphoblastic Leukemia (ALL) with Contemporary Therapy
Authors: Deepa Bhojwani, Deqing Pei, John Sandlund, Sima Jeha, Raul C. Ribeiro, Jeffrey E. Rubnitz, Susana C. Raimondi, Sheila Shurtleff, Mihaela Onciu, Cheng Cheng, Elaine Coustan-Smith, W. Paul Bowman, Scott C. Howard, Monika L. Metzger, Hiroto Inaba, Wing H. Leung, William E. Evans, Dario Campana, Mary V. Relling, Ching-Hon Pui
Journal: Blood (2010)
Characterization of T-Cell Lymphoma Cell Lines with a Novel t(9;14)(q34;q11.2) Rearrangement: Does gamma-Secretase Inhibitor Sensitivity Depend on Intragenic NOTCH1 Breakpoint?.
Authors: Shinsuke Suzuki, Stefan Nagel, Bjoern Schneider, Maren Kaufmann, Dorothea Anders, Hirohito Tsubouchi, Kimiharu Uozumi, Naomichi Arima, Hans G. Drexler, Roderick A.F. MacLeod
Journal: Blood (2006)
Control of cytokinesis by β-adrenergic receptors indicates an approach for regulating cardiomyocyte endowment
Authors: Honghai Liu, Cheng-Hai Zhang, Niyatie Ammanamanchi, Sangita Suresh, Christopher Lewarchik, Krithika Rao, Gerrida M. Uys, Lu Han, Maryline Abrial, Dean Yimlamai, Balakrishnan Ganapathy, Christelle Guillermier, Nathalie Chen, Mugdha Khaladkar, Jennifer Spaethling, James H. Eberwine, Junhyong Kim, Stuart Walsh, Sangita Choudhury, Kathryn Little, Kimberly Francis, Mahesh Sharma, Melita Viegas, Abha Bais, Dennis Kostka, Jun Ding, Ziv Bar-Joseph, Yijen Wu, Vijay Yechoor, Mousumi Moulik, Jennifer Johnson, Jacqueline Weinberg, Miguel Reyes-Múgica, Matthew L. Steinhauser, Bernhard Kühn
Journal: Science Translational Medicine (2019)

Control of cytokinesis by β-adrenergic receptors indicates an approach for regulating the established number of cardiomyocytes.
Cost-Implications Of Comorbidity For Autologous Hematopoietic Stem Cell Transplantation (Auto HSCT) In Elderly Patients With Multiple Myeloma (MM) Using The SEER-Medicare Database
Authors: Gunjan L. Shah, Aaron Winn, Andreas K. Klein, Kellie Sprague, Joshua T. Cohen, Kenneth B. Miller, Susan K. Parsons
Journal: Blood (2013)
The Influence of Polymorphisms of Interleukin-17F Genes On the Susceptibility and Clinical Outcome of Multiple Myeloma.
Authors: Takayuki Saitoh, Tetsuhiro Kasamatsu, Akihiko Yokohama, Hiroshi Handa, Norifumi Tsukamoto, Masamitsu Karasawa, Hatsue Ogawara, Yoshihisa Nojima, Hirokazu Murakami
Journal: Blood (2009)
A Phase 1 Clinical Trial of Selinexor in Combination with Decitabine in Patients with Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia
Authors: Bhavana Bhatnagar, Rebecca B. Klisovic, Alison R. Walker, Sumithra Vasu, Alice S. Mims, Katherine J. Walsh, Gregory K. Behbehani, James S. Blachly, Molly Vittorio, Qiuhong Zhao, Amy S. Ruppert, Shelley Orwick, Parvathi Ranganathan, John C. Byrd, William Blum, Ramiro Garzon
Journal: Blood (2016)
Prognostic Significance of FLT3/ITD Mutation in AML1/ETO-Associated Acute Myeloid Leukemia.
Authors: Yeo-Kyeoung Kim, Hee-Nam Kim, Il-Kwon Lee, Soo-Mee Bang, Deog-Yeon Jo, Jong-Ho Won, Chang-Yeol Yim, Deok-Hwan Yang, Je-Jung Lee, Hyeoung-Joon Kim
Journal: Blood (2007)
Somatic Mutations of ASXL1, RUNX1 and SETBP1 Improve Prognostic Stratification of Patients with Chronic Myelomonocytic Leukemia
Authors: Chiara Elena, Anna Gallì, Esperanza Such, Ulrich Germing, Ettore Rizzo, Jose Cervera, Elisabetta Molteni, Esther Schuler, Ilaria Ambaglio, Maria Lopez-Pavia, Silvia Zibellini, Andrea Kuendgen, Erica Travaglino, Reyes Sancho-Tello, Matteo G Della Porta, Ana Isabel Vicente, Guillermo F. Sanz, Luca Malcovati, Mario Cazzola
Journal: Blood (2014)
Monoclonal B-Cell Lymphocytosis (MBL) Is a Precursor State for Chronic Lymphocytic Leukemia (CLL) with 1% Progression Per Year.
Authors: Andy C. Rawstron, Fiona L. Bennet, Sheila J.M. O’Connor, Marwan Kwok, James A.L. Fenton, Marieth Plummer, Ruth M. de Tute, Roger G. Owen, Stephen J. Richards, Andrew S. Jack, Peter Hillmen
Journal: Blood (2007)
VLX1570, a First in Class Dub Inhibitor, Modulates BCR Signaling and CXCR4 Expression and Demonstrates Significant In Vivo Antitumor Activity in a Murine Model of Human Waldenstrom Macroglobulinemia
Authors: Aneel Paulus, Sharoon Akhtar, Kelara Samuel, Hassan Yousaf, Davitte Cogen, Jennifer Jiang, Abhisek Swaika, Anne Novak, Stephen M Ansell, Morie A Gertz, Robert A. Kyle, Thomas E. Witzig, George J Weiner, Peter Martin, Morton Coleman, Sikander Ailawadhi, Joachim Gullbo, Stig Linder, Geraldo Otero-Colon, Vivek Roy, Kasyapa S. Chitta, Asher Alban Chanan-Khan
Journal: Blood (2015)
Prospective Exploratory Phase II Studies of A Rotating Regime of Nilotinib and Imatinib for Frontline Treatment of Philadelphia POSITIVE (Ph+) Chronic Myeloid Leukemia (CML) and Acute Lymphoblastic Leukemia (ALL).
Authors: Giuseppe Saglio, Elisabetta Abruzzese, Giuliana Alimena, Monica Bocchia, Angelo Michele Carella, Renato Fanin, Giovanni Martinelli, Gianantonio Rosti, Domenico Russo, Giorgina Specchia, Michele Baccarani
Journal: Blood (2009)
A Pilot Trial of Unmatched Human Placenta-Derived Stem Cells (HPDSCs) in Conjunction with Unrelated Cord Blood Transplantation (UCBT) in Children and Young Adults with Malignant and Non-Malignant Disease (IND 14949)
Authors: Allyson M. Flower, Michelle Nash, Suzan Minzer, Lauren Harrison, Michael A Pulsipher, Qiuhu Shi, Debra Abrams, Roger H. Giller, Erin Morris, Olga Militano, Janet Ayello, Mildred Semidei-Pomales, Sandra Fabricatore, Xiaokui Zhang, Jodi Gurney, Carmella van de Ven, Cori M. Abikoff, Jessica C. Hochberg, Lee Ann Baxter-Lowe, Mitchell S. Cairo
Journal: Blood (2016)
Efficacy and Safety of Denileukin Diftitox (Ontak®) in the Treatment of Cutaneous T-Cell Lymphoma (CTCL) According to CD25 Status.
Authors: Francine Foss, Madeleine Duvic, Larisa Geskin, Joseph Anderson, Pierluigi Porcu, Raymond J. Hohl, Maureen Cooper, Jasmine M. Zain, John Zic, Patrica Hibberd, Mark Acosta
Journal: Blood (2006)
An Analysis of Early Toxicities, Associated Risk Factors and Survival during the First Year in Adults Undergoing Ex-Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies
Authors: Satyajit Kosuri, Diego Adrianzen Herrera, Michael Scordo, Gunjan Shah, Molly A. Maloy, Sean Devlin, Jimmy Nieves, Taylor Borrill, Scott T. Avecilla, Richard C. Meagher, Richard J. O'Reilly, Guenther Koehne, Brian C. Shaffer, Boglarka Gyurkocza, Hugo R. Castro-Malaspina, Roni Tamari, Sergio A. Giralt, Miguel Perales
Journal: Blood (2016)
Intra Bone Route of Donor Lymphocyte Infusions May Result with an Anti-Leukemic Effect Associated with an Accumulation of CD279+ Lymphocytes in the Marrow
Authors: Andrzej Lange, Monika Mordak-Domagala, Mariola Sedzimirska, Michalina Krydel, Helena Pakos, Jolanta Bochenska, Emilia Jaskula
Journal: Blood (2016)
Quality of Life (QoL) and Clinical Outcomes of Dasatinib Treatment in TKI-Naive and Early Switched from Imatinib Patients with Chronic Myeloid Leukemia in Chronic Phase (CP CML) in a Real World Setting
Authors: Tatyana Ionova, Natalia Bulieva, Olga Vinogradova, Kira Kurbatova, Elza Lomaia, Tatyana Nikitina, Natalia Novitskaya, Anna Rodionova, Elena Usacheva, Marina Chukavina, Marina Shumkova
Journal: Blood (2016)
A Phase III PETHEMA/GEM Study of Induction Therapy Prior Autologous Stem Cell Transplantation (ASCT) In Multiple Myeloma: Superiority of VTD (Bortezomib/Thalidomide/Dexamethasone) Over TD and VBMCP/VBAD Plus Bortezomib
Authors: Laura Rosiñol, María Teresa Cibeira, Maria Victoria Mateos, Joaquin Martinez, Albert Oriol, Ana Isabel Teruel, Dolores Hernández, José García-Laraña, Javier De La Rubia, Anna Sureda, Juan Besalduch, Luis Palomera, Yolanda Gonzalez, Maria Asunción Etxebeste, Joaquín Díaz-Mediavilla, Miguel T. Hernández, Felipe de Arriba, Adrian Alegre, Juan José Lahuerta, Jesus F San Miguel, Joan Blade
Journal: Blood (2010)
Single-Cell RNA Sequencing Resolves Spatiotemporal Development of Pre-thymic Lymphoid Progenitors and Thymus Organogenesis in Human Embryos
Authors: Yang Zeng, Chen Liu, Yandong Gong, Zhijie Bai, Siyuan Hou, Jian He, Zhilei Bian, Zongcheng Li, Yanli Ni, Jing Yan, Tao Huang, Hui Shi, Chunyu Ma, Xueying Chen, Jinyong Wang, Lihong Bian, Yu Lan, Bing Liu, Hongbo Hu
Journal: Immunity (2019)
RUNX1-ETO-Dependent Transcriptional Repression of RASSF2 Contributes to t(8;21) Leukemia through Evasion of MST1-Driven Apoptosis Signaling
Authors: Samuel A. Stoner, Elizabeth T. Andrews, Russell Dekelver, Stephanie Weng, Miao-Chia Lo, Kun-Liang Guan, Dong-Er Zhang
Journal: Blood (2016)
Chimerism and Tolerance Without Gvhd In Mismatched Recipients Of Combined Hematopoietic Stem Cell/Kidney Transplants: Donor-Specific Hyporeactivity Is Not a Reliable Biomarker For Tolerance
Authors: Joseph Leventhal, Michael Abecassis, Joshua Miller, Lorenzo Gallon, David J. Tollerud, Mary Jane Elliott, Suzanne T. Ildstad
Journal: Blood (2013)
Bosutinib (SKI-606) Demonstrates Clinical Activity and Is Well Tolerated among Patients with AP and BP CML and Ph+ ALL.
Authors: C. Gambacorti-Passerini, H. Kantarjian, T. Bruemmendorf, G. Martinelli, M. Baccarani, T. Fischer, E.M. Pogliani, B. Hewes, A.D.G. Volkert, N. Bardy-Bouxin, J. Cortes
Journal: Blood (2007)
High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes
Authors: Tomas Vaisar, Jenny E. Kanter, Jake Wimberger, Angela D. Irwin, John Gauthier, Emily Wolfson, Vanessa Bahnam, I-Hsien Wu, Hetal Shah, Hillary A. Keenan, Carla J. Greenbaum, George L. King, Jay W. Heinecke, Karin E. Bornfeldt
Journal: Diabetes Care (2019)

A subset of people with long-standing type 1 diabetes (T1D) appears to be protected from microvascular and macrovascular complications. Previous studies have focused on improved abilities to respond to glucose and its downstream effects as protective mechanisms. It is unclear whether lipoproteins play a role in the vascular health of these people. We therefore determined whether HDL particle concentration, size, function, and/or protein composition associate with protection from vascular complications.We studied two independent cross-sectional cohorts with T1D: the T1D Exchange Living Biobank (n = 47) and the Joslin Medalist Study (n = 100). Some of the subjects had vascular complications, whereas others never exhibited vascular complications, despite an average duration of diabetes in the cohorts of 45 years. We assessed HDL particle size and concentration by calibrated ion mobility analysis, the HDL proteome by targeted mass spectrometry, and HDL function ex vivo by quantifying cholesterol efflux capacity and inhibition of monocyte adhesion to endothelial cells.In both cohorts, people without vascular complications exhibited significantly higher concentrations of medium-sized HDL particles (M-HDL) independently of total and HDL cholesterol levels. While no consistent differences in HDL functions were observed ex vivo, people without vascular complications had higher levels of HDL-associated paraoxonase 1 (PON1), an enzyme that inhibits atherosclerosis in animal models.Elevated concentrations of M-HDL particles and elevated levels of HDL-associated PON1 may contribute to long-term protection from the vascular complications of diabetes by pathways that are independent of total cholesterol and HDL cholesterol.
HIV-Infected T Cells Induce Granzyme B-Secreting Regulatory B Cells in An Interleukin 21-Dependent Fashion,
Authors: Christof Kaltenmeier, Karen Dahlke, Ali Gawanbacht, Thamara Beyer, Stefanie Hofmann, Georg Härter, Beate Grüner, Peter Kern, Frank Kirchhoff, Hubert Schrezenmeier, Bernd Jahrsdörfer
Journal: Blood (2011)
Erratum. Preoperative Circulating Succinate Levels as a Biomarker for Diabetes Remission After Bariatric Surgery. Diabetes Care 2019;42:1956–1965
Authors: Victoria Ceperuelo-Mallafré, Gemma Llauradó, Noelia Keiran, Ester Benaiges, Brenno Astiarraga, Laia Martínez, Silvia Pellitero, Jose Miguel González-Clemente, Amaia Rodríguez, José Manuel Fernández-Real, Albert Lecube, Ana Megía, Nuria Vilarrasa, Joan Vendrell, Sonia Fernández-Veledo
Journal: Diabetes Care (2019)

In the article cited above, the clinical trial number was mistakenly given as NCT1410475, clinicaltrials.gov. …
Plasma ‘Free’ HB Is Related to Red Cell Derived Vesicle Numbers in Sickle Cell Anemia and Thalassemia Intermedia: Implications for Nitric Oxide (NO) Scavenging and Pulmonary Hypertension.
Authors: Maxwell Westerman, Arnold Pizzey, Jocelyn Hirschman, Mario Cerino, Ada Eze, Priya Ramoton, Yonit Weil-Weiner, John Porter
Journal: Blood (2004)
The Frequency of Genetic Mutations in T-MN Is High and Comparable to Primary MDS but the Spectrum Is Different
Authors: Deepak Singhal, L Amilia Wee, Wendy T Parker, Sarah Moore, Milena Babic, Jinghua Feng, Andreas W Schreiber, Joel Geoghegan, Monika M Kutyna, Rakchha Chhetri, Peter G Bardy, Shriram V. Nath, Nimit Singhal, Raghvendra Gowda, Luen Bik To, Richard D'Andrea, David M. Ross, Ian D Lewis, Christopher N Hahn, Hamish S Scott, Devendra K Hiwase
Journal: Blood (2016)
Sustained fever associated with immune checkpoint inhibitors may be a poor prognostic factor
Authors: Hiroki Ueda, Eriko Murakami, Yuka Okuda, Eri Takase, Takahiro Kaki, Yuhei Harutani, Nao Yamagata, Katsuyuki Furuta, Chigusa Shimono, Nobuyuki Yamamoto
Journal: Annals of Oncology (2019)
Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome in Lymphoma Patients Receiving Hematopoietic Cell Transplantation
Authors: Satoshi Yamasaki, Ritsuro Suzuki, Kaoru Hatano, Kentaro Fukushima, Hiroatsu Iida, Satoko Morishima, Youko Suehiro, Takahiro Fukuda, Naoyuki Uchida, Takashi Uchiyama, Yoshiko Atsuta, Junji Suzumiya
Journal: Blood (2016)
The Significance of Palifermin (Kepivance) in Reduction of Oral Mucositis (OM) Incidence and Acute Graft Versus Host Disease (aGvHD) in Patients with Hematological Diseases Undergoing HSCT.
Authors: B. Nasilowska-Adamska, P. Rzepecki, J. Manko, A. Czyz, M. Markiewicz, I. Fedorowicz, A. Tomaszewska, B. Piatkowska-Jakubas, A. Wrzesien-Kus, M. Bieniaszewska, D. Duda, K. Halaburda, A. Szczepinski, A. Lange, A. Hellman, T. Robak, A. Skotnicki, Wieslaw W. Jedrzejczak, J. Walewski, J. Holowiecki, M. Komarnicki, A. Dmoszynska, K. Warzocha, B. Marianska
Journal: Blood (2006)
The difference in the effects on chemotherapy following primary tumor resection and olostomy in colorectal cancer
Authors: Yusuke Nagata, Ryoichi Sawada, Masahisa Ohkuma, Takashi Nishimura, Masaaki Noguchi, Yasuhiro Takeda, Daisuke Ito, Eijiro Nagasaki, Katsushi Amano, Ken Eto, Katsuhiko Yanaga, Masayuki Saruta
Journal: Annals of Oncology (2019)
Glycosylation-Related Gene Expression Is Dysregulated in Multiple Myeloma and Overexpression of the Sialyltransferase ST3GAL6 Is Associated with Inferior Survival.
Authors: Siobhan V Glavey, Stephen Cunningham, Laura S Murillo, Catherine Loughrey, Ping Wu, Michael Cairns, Satbir Kaur Gill, Anja Kruger, Jared Q Gerlach, Marian Kane, Gareth J. Morgan, Lokesh Joshi, Michael E O'Dwyer
Journal: Blood (2012)
A European Collaborative Study of Treatment Outcomes In 428 Patients with Systemic AL Amyloidosis
Authors: Ashutosh D Wechalekar, Efstathios Kastritis, Giampaolo Merlini, Philip N Hawkins, Meletios A. Dimopoulos, Julian D Gillmore, Simon DJ Gibbs, Giovanni Palladini
Journal: Blood (2010)
Is prophylactic percutaneous endoscopic gastrostomy necessary for chemoradiotherapy after total laryngectomy?
Authors: Hidenori Kimura, Satoshi Hamauchi, Sadayuki Kawai, Yusuke Onozawa, Hirofumi Yasui, Aiko Yamashita, Hirofumi Ogawa, Tsuyoshi Onoe, Tomoyuki Kamijo, Yoshiyuki Iida, Tetsuro Onitsuka, Tomoya Yokota
Journal: Annals of Oncology (2019)
High Dose Therapy / ASCT with Rituximab for In-Vivo Purging and Post-ASCT Consolidation in Relapsed Follicular Lymphoma Achieves Prolonged Clinical and Molecular Remissions.
Authors: Anthony C. Woods, Rena Buckstein, Joy Mangel, Kevin Imrie, David Spaner, Michael Crump, Nancy Pennell, Angela Boudreau, Marciano Reis, Neil Berinstein
Journal: Blood (2004)
Daratumumab Directly Induces Human Multiple Myeloma Cell Death and Acts Synergistically with Conventional and Novel Anti-Myeloma Drugs
Authors: Sun-Young Kong, Xian-Feng Li, Sabikun Nahar, Weihua Song, Michel de Weers, Paul W.H.I. Parren, Paul Richardson, Nikhil C. Munshi, Kenneth C. Anderson, Yu-Tzu Tai
Journal: Blood (2010)
Limited Role of Workup Including PET-CT, Esophagogastroduodenoscopy and Bone Marrow Biopsy in Staging of Ocular Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type
Authors: Heejung Chae, Cheolwon Suh, Dok Hyun Yoon, Jung Yong Hong, Chan-Sik Park, Jooryung Huh, Ho-Seok Sa, Kyoung Won Kim
Journal: Blood (2016)
Role of Nitric Oxide Carried by Hemoglobin in Cardiovascular Physiology
Authors: Richard T. Premont, James D. Reynolds, Rongli Zhang, Jonathan S. Stamler
Journal: Circulation Research (2019)

A continuous supply of oxygen is essential for the survival of multicellular organisms. The understanding of how this supply is regulated in the microvasculature has evolved from viewing erythrocytes (red blood cells [RBCs]) as passive carriers of oxygen to recognizing the complex interplay between Hb (hemoglobin) and oxygen, carbon dioxide, and nitric oxide-the three-gas respiratory cycle-that insures adequate oxygen and nutrient delivery to meet local metabolic demand. In this context, it is blood flow and not blood oxygen content that is the main driver of tissue oxygenation by RBCs. Herein, we review the lines of experimentation that led to this understanding of RBC function; from the foundational understanding of allosteric regulation of oxygen binding in Hb in the stereochemical model of Perutz, to blood flow autoregulation (hypoxic vasodilation governing oxygen delivery) observed by Guyton, to current understanding that centers on S-nitrosylation of Hb (ie, S-nitrosohemoglobin; SNO-Hb) as a purveyor of oxygen-dependent vasodilatory activity. Notably, hypoxic vasodilation is recapitulated by native S-nitrosothiol (SNO)-replete RBCs and by SNO-Hb itself, whereby SNO is released from Hb and RBCs during deoxygenation, in proportion to the degree of Hb deoxygenation, to regulate vessels directly. In addition, we discuss how dysregulation of this system through genetic mutation in Hb or through disease is a common factor in oxygenation pathologies resulting from microcirculatory impairment, including sickle cell disease, ischemic heart disease, and heart failure. We then conclude by identifying potential therapeutic interventions to correct deficits in RBC-mediated vasodilation to improve oxygen delivery-steps toward effective microvasculature-targeted therapies. To the extent that diseases of the heart, lungs, and blood are associated with impaired tissue oxygenation, the development of new therapies based on the three-gas respiratory system have the potential to improve the well-being of millions of patients.
The Expression Signature of M3 AML Suggests Direct and Indirect Effects of PML-RARA on Target Genes.
Authors: Jacqueline E. Payton, Nicole R. Grieselhuber, Li-Wei Chang, Mark A. Murakami, Wenlin Yuan, Daniel C. Link, Rakesh Nagarajan, Mark A. Watson, Timothy J. Ley
Journal: Blood (2007)
Newly Diagnosed Diffuse Large B-Cell Lymphoma Patients Treated with Immunochemotherapy Who Are Alive and Progression Free 12 Months After Diagnosis Have a Subsequent Overall Survival Similar to That of the General Population
Authors: Matthew J Maurer, Herve Ghesquieres, Thomas E. Witzig, Carrie A. Thompson, Ivana N. Micallef, William R Macon, Sergei I Syrbu, Paul Kurtin, Cristine Allmer, Therese Gargi, Emmanuelle Nicolas-Virelizier, Catherine Sebban, Susan L Slager, Thomas M Habermann, Brian K Link, James R Cerhan
Journal: Blood (2012)
Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.
Authors: Fabien Le bras, Marie Sebert, Charikleia Kelaidi, Thierry Lamy, Francois Dreyfus, Jacques Delaunay, Anne Banos, Michel Blanc, Norbert Vey, Martine Gardembas, Sorin Visanica, Frederic Bauduer, Pascal Turlure, Mehdi Dahoun, Odile Beyne-Rauzy, Agnes Guerci, Alain Delmer, Stephane de Botton, Christian Berthou, Caroline Besson, Delphine Rea, Francois Lefrere, Eric Wattel, Philippe Rousselot, Pierre Fenaux, Lionel Ades
Journal: Blood (2009)